AnaptysBio, Inc.
ANAB
$64.72
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 157.01% | 196.42% | 304.17% | 387.20% | 432.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 157.01% | 196.42% | 304.17% | 387.20% | 432.03% |
| Cost of Revenue | -17.01% | -1.15% | 14.20% | 25.01% | 23.86% |
| Gross Profit | 235.93% | 116.87% | 64.02% | 49.64% | 36.97% |
| SG&A Expenses | 19.69% | 6.29% | 8.11% | 1.64% | 1.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.47% | 0.45% | 12.82% | 19.30% | 18.37% |
| Operating Income | 141.67% | 79.53% | 44.45% | 35.25% | 26.82% |
| Income Before Tax | 91.00% | 48.96% | 22.10% | 13.92% | 11.24% |
| Income Tax Expenses | 5,366.67% | 1,440.00% | 1,440.00% | 1,275.00% | 175.00% |
| Earnings from Continuing Operations | 90.89% | 48.91% | 22.06% | 13.89% | 11.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.89% | 48.91% | 22.06% | 13.89% | 11.24% |
| EBIT | 141.67% | 79.53% | 44.45% | 35.25% | 26.82% |
| EBITDA | 142.38% | 79.85% | 44.59% | 35.35% | 26.90% |
| EPS Basic | 94.31% | 53.92% | 29.37% | 21.00% | 14.41% |
| Normalized Basic EPS | 94.42% | 51.77% | 26.19% | 17.31% | 10.34% |
| EPS Diluted | 89.96% | 53.57% | 29.32% | 20.95% | 14.36% |
| Normalized Diluted EPS | 90.09% | 51.39% | 26.19% | 17.31% | 10.34% |
| Average Basic Shares Outstanding | -23.09% | 7.39% | 10.72% | 10.12% | 5.37% |
| Average Diluted Shares Outstanding | 3.52% | 8.47% | 10.72% | 10.12% | 5.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |